Abstract Details

Title Gait Patterns in HIV: Effects of Age, Gender and Disease

Topic Infections/AIDS/Prion Disease

Presentation(s) S16 - (-)

Poster/Presentation
Number 004

Objective

Background There is a paucity of information on early clinical markers for progression of aging in HIV -infected persons, a rapidly growing disease population. While motor and cognitive dysfunctions are common, occurring early in infection, a comprehensive examination of gait parameters in HIV has been lacking.

Design/Methods We conducted quantitative gait assessments in 125 HIV-infected patients aged 22 to 79 years. We compared the gait performance on eight selected parameters in 45 HIV participants age 50 and older versus 80 younger participants. We also compared gait in 23 HIV participants 65 and older versus 50 age and sex matched non-HIV controls. Finally, we examined gait characteristics in 125 HIV-infected patients by HIV dementia stages.

Results We generated normative data by age and sex in HIV-infected patients on eight gait variables. Velocity (older 85.1 vs. younger 99.55 cm/s) and stride length (older 108.45 vs. younger 119.55 cm) were the only gait variables among the eight examined that showed age group differences. Mean stride length (100.51 vs. 122.94), double support time (0.56 vs. 0.35) and stride length variability (4.95 vs. 2.50) were worse in the HIV-infected group compared to the non-HIV-infected controls. Participants showed a significant difference towards declining velocity and stride length across HIV dementia stages.

Conclusions The normative gait data provided here could be utilized to improve detection of early gait impairment in HIV-infected patients, may be useful in the future in improving staging of HIV infection related dementia, and warrants further study as predictors of cognitive and mobility outcomes.

Authors/Disclosures
Raminder K. Parihar, MD (Montefiore Medical Center) PRESENTER	Dr. Parihar has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Joe Verghese, MD, FAAN (Albert Einstein College of Medicine)	Dr. Verghese has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MedRhythms Inc. The institution of Dr. Verghese has received research support from National Institutes of Health.
	No disclosure on file

��ɫ��

��ɫ��